Literature DB >> 32078014

Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.

Hao Wu1,2, Haipeng Tong1,2, Xuesong Du1,2, Hong Guo1,2, Qiang Ma3, Yulong Zhang1,2, Xiaoyue Zhou4, Heng Liu1,2, Sunan Wang1,2, Jingqin Fang5, Weiguo Zhang6,7.   

Abstract

OBJECTIVE: The current study aimed to evaluate the clinical practice for hemodynamic tissue signature (HTS) method in IDH genotype prediction in three groups derived from high-grade gliomas.
METHODS: Preoperative MRI examinations of 44 patients with known grade and IDH genotype were assigned into three study groups: glioblastoma multiforme, grade III, and high-grade gliomas. Perfusion parameters were analyzed and were used to automatically draw the four reproducible habitats (high-angiogenic enhancing tumor habitats, low-angiogenic enhancing tumor habitats, infiltrated peripheral edema habitats, vasogenic peripheral edema habitats) related to vascular heterogeneity. These four habitats were then compared between inter-patient with IDH mutation and their wild-type counterparts at these three groups, respectively. The discriminating potential for HTS in assessing IDH mutation status prediction was assessed by ROC curves.
RESULTS: Compared with IDH wild type, IDH mutation had significantly decreased relative cerebral blood volume (rCBV) at the high-angiogenic enhancing tumor habitats and low-angiogenic enhancing tumor habitats. ROC analysis revealed that the rCBVs in habitats had great ability to discriminate IDH mutation from their wild type in all groups. In addition, the Kaplan-Meier survival analysis yielded significant differences for the survival times observed from the populations dichotomized by low (< 4.31) and high (> 4.31) rCBV in the low-angiogenic enhancing tumor habitat.
CONCLUSIONS: The HTS method has been proven to have high prediction capabilities for IDH mutation status in high-grade glioma patients, providing a set of quantifiable habitats associated with tumor vascular heterogeneity. KEY POINTS: • The HTS method has a high accuracy for molecular stratification prediction for all subsets of HGG. • The HTS method can give IDH mutation-related hemodynamic information of tumor-infiltrated and vasogenic edema. • IDH-relevant rCBV difference in habitats will be a great prognosis factor in HGG.

Entities:  

Keywords:  Glioblastoma; Hemodynamics; Isocitrate dehydrogenase; Prognosis

Year:  2020        PMID: 32078014     DOI: 10.1007/s00330-020-06702-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  12 in total

1.  Reliability of dynamic susceptibility contrast perfusion metrics in pre- and post-treatment glioma.

Authors:  Valentina Kouwenberg; Lusien van Santwijk; Frederick J A Meijer; Dylan Henssen
Journal:  Cancer Imaging       Date:  2022-06-17       Impact factor: 5.605

Review 2.  Updates in IDH-Wildtype Glioblastoma.

Authors:  Mary Jane Lim-Fat; James R Perry; Jawad M Melhem; Jay Detsky
Journal:  Neurotherapeutics       Date:  2022-05-31       Impact factor: 6.088

3.  Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge.

Authors:  Vittorio Stumpo; Martina Sebök; Christiaan Hendrik Bas van Niftrik; Katharina Seystahl; Nicolin Hainc; Zsolt Kulcsar; Michael Weller; Luca Regli; Jorn Fierstra
Journal:  MAGMA       Date:  2021-12-07       Impact factor: 2.310

4.  Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas.

Authors:  Paola Feraco; Antonella Bacci; Patrizia Ferrazza; Luc van den Hauwe; Riccardo Pertile; Salvatore Girlando; Mattia Barbareschi; Cesare Gagliardo; Alessio Giuseppe Morganti; Benedetto Petralia
Journal:  Diagnostics (Basel)       Date:  2020-04-23

5.  Long non-coding RNA TP73-AS1 is a potential immune related prognostic biomarker for glioma.

Authors:  Bo Zhang; Qinglin Li; Bin Wu; Shuyuan Zhang; Liwen Li; Kai Jin; Sheng Li; Kai Li; Zeng Wang; Yi Lu; Liang Xia; Caixing Sun
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

6.  Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM.

Authors:  Luca Pasquini; Antonio Napolitano; Emanuela Tagliente; Francesco Dellepiane; Martina Lucignani; Antonello Vidiri; Giulio Ranazzi; Antonella Stoppacciaro; Giulia Moltoni; Matteo Nicolai; Andrea Romano; Alberto Di Napoli; Alessandro Bozzao
Journal:  J Pers Med       Date:  2021-04-09

7.  Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.

Authors:  María Del Mar Álvarez-Torres; Elies Fuster-García; Javier Juan-Albarracín; Gaspar Reynés; Fernando Aparici-Robles; Jaime Ferrer-Lozano; Juan Miguel García-Gómez
Journal:  BMC Cancer       Date:  2022-01-06       Impact factor: 4.430

Review 8.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.

Authors:  Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

9.  MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas.

Authors:  Elies Fuster-Garcia; David Lorente Estellés; María Del Mar Álvarez-Torres; Javier Juan-Albarracín; Eduard Chelebian; Alex Rovira; Cristina Auger Acosta; Jose Pineda; Laura Oleaga; Enrique Mollá-Olmos; Silvano Filice; Paulina Due-Tønnessen; Torstein R Meling; Kyrre E Emblem; Juan M García-Gómez
Journal:  Eur Radiol       Date:  2020-10-01       Impact factor: 5.315

10.  DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study.

Authors:  Vera C Keil; Gerrit H Gielen; Bogdan Pintea; Peter Baumgarten; Angeliki Datsi; Kanishka Hittatiya; Matthias Simon; Elke Hattingen
Journal:  Clin Neuroradiol       Date:  2021-04-26       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.